MDM2 and neoplasm: This hypothesis is based on the fact that estrogen can regulate MDM2 levels, in part, via a promoter site adjacent to SNP309 and thus in pre-menopausal women, where there are higher levels of circulating estrogen, and in tumours that express high levels of the estrogen receptor, the effects of SNP309 may be exacerbated [24].